| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-05-31 | lucitanib | advanced solid tumors |
1-2 | Clovis Oncology (USA) | Cancer - Oncology |
| 2014-05-31 | ABT-414 | glioblastoma |
1 | AbbVie (USA - IL) Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2014-05-31 | polatuzumab vedotin, pinatuzumab vedotin | relapsed/refractory non-Hodgkin lymphoma | 2 | Genentech, a member of the Roche Group (USA - Switzerland) Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2014-05-31 | DNIB0600A | non-small cell lung cancer, platinum-resistant ovarian cancer | 1 | Genentech, a member of the Roche Group (USA - Switzerland) Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2014-05-31 | DSTP3086S | metastatic prostate cancer | 1 | Genentech, a member of the Roche Group (USA - Switzerland) Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2014-05-31 | AV-203 | metastatic or advanced solid tumors |
1 | Aveo Oncology (USA - MA) | Cancer - Oncology |
| 2014-05-31 | RG7155 | locally advanced pigmented villonodular synovitis (PVNS) |
1 | Roche (Switzerland) | Cancer - Oncology |
| 2014-05-31 | combination of olaparib and cediranib | ovarian cancer |
2 | AstraZeneca (UK) | Cancer - Oncology |
| 2014-05-31 | Iclusig® (ponatinib) | newly diagnosed chronic-phase chronic myeloid leukemia |
3 | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2014-05-30 | DMOT4039A | pancreatic cancer ovarian cancer |
1 | Genentech, a member of the Roche Group (USA - Switzerland) | Cancer - Oncology |
| 2014-05-30 | TH-302 | recurrent glioblastoma |
1-2 | Threshold Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2014-05-30 | subcutaneous formulation of ofatumumab | neuromyelitis optica | GSK (UK) | Rare diseases | |
| 2014-05-30 | subcutaneous ofatumumab | relapsing-remitting multiple sclerosis |
3 | GSK (UK) | Neurodegenerative diseases |
| 2014-05-30 | sevuparin | malaria |
1-2 | Dilaforette (Sweden) Mahidol - Oxford Tropical Medicine Research Unit (MORU) | Infectious diseases - Parasitic diseases |
| 2014-05-29 | Sym004 | metastatic colorectal cancer (mCRC) |
1-2 | Symphogen (Denmark) | Cancer - Oncology |
| 2014-05-28 | 4SC-202 | advanced hematological indications | 1 | 4SC (Germany) | Cancer - Oncology |
| 2014-05-28 | Debio 0932 | advanced non-small cell lung cancer (NSLC) |
1-2 | Curis (USA) Debiopharm (Switzerland) | Cancer - Oncology |
| 2014-05-28 | Debio 0932 | non-small cell lung cancer (NSCLC) renal cell carcinoma (RCC) |
preclinical | Debiopharm (Switzerland) Curis (USA) | Cancer - Oncology |
| 2014-05-28 | Debio 0932 | solid tumours |
1 | Debiopharm (Switzerland) | Cancer - Oncology |
| 2014-05-27 | IMAB362 | gastroesophageal cancer | 2a | Ganymed Pharmaceuticals (Germany) | Cancer - Oncology |
